Keywords: immunomedics, veltuzumab, shows, rate, biopharmaceutical, company, reported

Immunomedics' veltuzumab shows 68% OR rate

Article | 08 June 2009

US biopharmaceutical company Immunomedics reported a 68% overall response rate in patients with immune thrombocytopenic purpura treated with low doses of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Amino Acids

Injection

Physostigmine Salicylate

Go to drug listing